Shares of T2 Biosystems Inc. (NASDAQ:TTOO) traded down 1.7% during mid-day trading on Monday . The stock traded as low as $5.20 and last traded at $5.34, with a volume of 78,798 shares trading hands. The stock had previously closed at $5.43.

Several analysts recently issued reports on the stock. Janney Montgomery Scott downgraded shares of T2 Biosystems from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 12th. Canaccord Genuity reduced their price target on shares of T2 Biosystems from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, April 12th. Zacks Investment Research downgraded shares of T2 Biosystems from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th. Cantor Fitzgerald reissued a “buy” rating on shares of T2 Biosystems in a research report on Tuesday, May 3rd. Finally, Leerink Swann reissued a “buy” rating on shares of T2 Biosystems in a research report on Monday, May 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $11.03.

The company has a 50 day moving average price of $7.40 and a 200-day moving average price of $8.53. The firm’s market cap is $127.01 million.

T2 Biosystems (NASDAQ:TTOO) last issued its earnings results on Monday, May 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.01. The firm earned $1.10 million during the quarter. The firm’s revenue for the quarter was up 485.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.53) EPS. On average, equities analysts predict that T2 Biosystems Inc. will post ($2.17) earnings per share for the current fiscal year.

In other news, SVP Rahul Dhanda sold 3,589 shares of the company’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $8.16, for a total value of $29,286.24. Following the sale, the senior vice president now owns 3,589 shares in the company, valued at $29,286.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

An institutional investor recently raised its position in T2 Biosystems stock. Aisling Capital LLC increased its position in T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems makes up about 5.3% of Aisling Capital LLC’s investment portfolio, making the stock its 6th largest position. Aisling Capital LLC owned approximately 13.89% of T2 Biosystems worth $30,971,000 as of its most recent SEC filing.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.